Gurugram, India

Minakshi Garg

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Fresenius Kabi Oncology Limited. Active years: 2017-2018.


% Patents Active = 50.0

 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Minakshi Garg: Innovator in Pharmaceutical Compositions

Introduction

Minakshi Garg is a prominent inventor based in Gurgaon, India. She has made significant contributions to the field of pharmaceuticals, particularly in developing stable compositions for compounds susceptible to hydrolysis. With a total of 2 patents, her work is vital for advancing medical treatments.

Latest Patents

Minakshi Garg's latest patents include a process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis. This invention outlines a method that involves the addition of pharmaceutically acceptable lyophilization excipients, the use of organic solvents, and maintaining specific temperature ranges to ensure stability. Another notable patent is for a stable pharmaceutical composition of 5-aza-2'-deoxycitidine, which comprises non-aqueous formulations that can be used for treating patients with myelodysplastic syndromes.

Career Highlights

Minakshi Garg is currently employed at Fresenius Kabi Oncology Limited, where she continues to innovate in the pharmaceutical sector. Her expertise in creating stable formulations has positioned her as a key player in her field.

Collaborations

Minakshi has collaborated with notable colleagues such as Dhiraj Khattar and Rajesh Khanna, contributing to various projects that enhance pharmaceutical development.

Conclusion

Minakshi Garg's work in pharmaceutical innovations showcases her dedication to improving medical treatments through her inventive processes. Her contributions are essential for the advancement of stable pharmaceutical compositions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…